American MNC pharmaceutical corporation Pfizer Inc has started human safety testing of a new pill for treating the novel coronavirus that, according to the company, could be used at the first sign of illness.
The US drugmaker that brought out the first authorised Covid-19 vaccine in the US with German BioNTech, has also said that the antiviral candidate displayed potent activity against SARS-CoV-2 or the virus that causes the novel coronavirus, in lab studies.
The company’s candidate PF-07321332 is a protease inhibitor, which prohibits the virus from replicating in cells. Protease inhibitors, the company said, have been effective for treating other viral pathogens, including HIV and hepatitis C virus, on their own as well as in combination with other antivirals.
The company believes this molecules class may offer well-tolerated treatments against the novel coronavirus, as the presently-marketed therapeutics that are working on the same lines have not reported safety concerns.